——医药生物行业学习《2026 年政府工作报告》体会 行业研究 开启多元支付、银发经济新纪元，关注 AI 医疗、脑机接口等新方向 2026 年 3 月 5 日 增持（维持） 要点 事件：《 2026 年政府工作报告》发布，多处内容涉及医药生物，包括明确打造 生物医药等新兴支柱产业、培育脑机接口等未来产业，报告提及实施医疗卫生 强基工程、完善儿科和精神卫生服务体系、有效防控基孔肯雅热等传染病疫情、 健全基本医保参保长效机制、优化医药集采措施、推出商业健康保险创新药目 录、长期护理保险制度覆盖３亿人等。 点评： 商保目录与长护险打开支付端增量空间。《报告》明确提出要"推出商业健康 保险创新药目录"， 我们认为过去创新药高度依赖进入《国家基本医保目录》 以实现放量，此次提出建立商保专属目录，标志着"基本医保支撑广度、商业 医保支撑高度"的多元支付格局逐步成熟。我们认为有望显著改善创新药的商 业化环境。其次，报告提到要"开展养老服务消费补贴试点"，其中特别提及 要"实施中度以上失能老年人养老服务消费补贴项目"。随着长护险覆盖面的 扩大和专项补贴的实施，有望解决银发消费中支付端的底层问题，直接驱动康 复医疗器械（如智能 ...

重点关注 Q1 业绩预期、积极把握主题机会；手术机器人专题：政 策打通商业化瓶颈、千亿市场驶向发展快车道 医药生物 证券研究报告/行业定期报告 2026 年 03 月 02 日 -医药生物行业 3 月月报 | | | | | | 简称 | 股价 | | | EPS | | | | | PE | | | 评级 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 分析师：祝嘉琦 | | | （元） | 2023A | 2024A | 2025E | 2026E | 2027E | 2023A | 2024A | 2025E | 2026E | 2027E | | | 执业证书编号：S0740519040001 | | 药明生物 三生国健 | 40.22 | 0.82 | 0.81 | 0.96 | 1.17 | 1.47 | 48.95 | 49.59 | 42.00 | 34.37 | 27.42 | 买入 | | | | | 59.38 | 0.48 | 1.14 | 4 ...

证 券 研 究 报 告 行业周报 医药供给端变量增加 医药行业周报 投资评级： 报告日期： 推荐 （ 维持 ） 2026年03月01日 分析师：胡博新 SAC编号：S1050522120002 分析师：吴景欢 SAC编号：S1050523070004 医 药 行 业 观 点 1.供给端变量增加，提价范围进一步扩大 受反内卷、两用物项管理、反倾销等一系列政策影响，医药供给端变量增加，促进价格周期的转变。首先原料药产业供给 端变化最为敏感，青霉素产业链已开始价格的反弹。2026年1月末，印度商工部外贸总局（DGFT）发布对青霉素工业盐、 6-APA和阿莫西林的进口限价，其中6-APA限价为3405 印度卢比/公斤，截止日期至 2027-01-28。按照印度的限价标准，6- APA折合人民币约260元/kg，高于目前出口报价，国内企业已开始逐步提高报价。2月25日起星湖伊品计划对赖氨酸、苏氨 酸及小品种氨基酸上调50-300元/吨，同日，象屿生化苏氨酸报价上调300元/吨。从产能供给来看，包括赖氨酸、苏氨酸和 蛋氨酸在内的饲用氨基酸添加剂供给都过剩，但2025年下半年以来价格普遍处于低位，行业开工率普遍不足，产量的 ...

Core Viewpoint - The A-share market has shown active trading with significant focus on sectors like chemicals and non-ferrous metals, driven by price increases and strong performance in ETFs related to these sectors [1][2]. Group 1: Market Performance - The A-share market closed February with the Shanghai Composite Index achieving three consecutive monthly gains, with daily trading volumes exceeding 1 trillion yuan becoming a norm [1]. - On February 27, the total trading volume in the Shanghai, Shenzhen, and Beijing markets reached 2.51 trillion yuan, slightly down by 504 billion yuan from the previous day [1]. - Over 3,200 stocks in the market saw gains, with notable performances in small metals and rare earths, leading to a surge in stocks like Hunan Gold [1]. Group 2: Sector Highlights - The non-ferrous metals sector continued to perform strongly, with the non-ferrous ETF (159876) reaching a peak increase of 3.82% and closing up 3.74% on the day [4]. - The chemical sector benefited from rising prices, with the chemical ETF (516020) achieving four consecutive daily gains, marking its highest point since January 2022 [1][4]. - The AI sector is gaining traction, with domestic AI usage surpassing that of the US, benefiting the domestic AI industry chain, as reflected in the performance of the innovation-focused AI ETF (589520) [1]. Group 3: ETF Performance - The electric power ETF (159146) saw a significant increase of 2.64%, reaching a new high since its listing, driven by the rising demand for electricity due to AI development [2][10]. - The largest medical ETF (512170) in the market rose by 1.14%, recovering its annual line, with a net inflow of over 1.9 billion yuan in the previous three days [14][16]. - The electric power sector is viewed as a defensive investment amid the AI boom, with the electric power ETF focusing on various energy sources including thermal, hydro, wind, nuclear, and solar power [12]. Group 4: Future Outlook - Analysts suggest that the non-ferrous metals sector still has upward momentum, supported by supply disruptions and high demand, with a focus on precious, industrial, battery, and strategic metals [7]. - The medical sector is expected to recover, with growth opportunities arising from performance recovery, overseas expansion, brain-computer interfaces, and AI in healthcare [16][18].

证券日报网讯2月27日，美好医疗（301363）在互动平台回答投资者提问时表示，截至2026年2月10日， 公司股东总户数为28329户。 ...

（文章来源：证券日报） 证券日报网讯 2月27日，美好医疗在互动平台回答投资者提问时表示，截至2026年2月13日，公司股东 总户数为28688户。 ...

脑机接口+CRO概念+传感器+医疗器械概念+人民币贬值受益 1、根据2025年12月12日互动易：公司正与下游脑机接口客户深入开展产品合作，协助客户实现从实验 室研发到批量出货的高效商业化转化，目前相关业务产生的收入规模较小，具体客户合作细节涉及商业 机密不便回复。 2、2023年9月1日公告：公司专注于医疗器械领域，为全球医疗器械百强客户以及细分市场龙头企业提 供CDMO和CRO的一站式服务。 来源：新浪证券-红岸工作室 2月27日，美好医疗涨3.89%，成交额4.59亿元，换手率3.98%，总市值177.89亿元。 异动分析 技术面：筹码平均交易成本为32.71元 该股筹码平均交易成本为32.71元，近期该股有吸筹现象，但吸筹力度不强；目前股价靠近支撑位 31.02，注意支撑位处反弹，若跌破支撑位则可能会开启一波下跌行情。 3、根据2025年9月22日互动易：公司自研压力传感器和NO电化学传感器分别用于肺功能仪和哮喘检测 仪产品，毫米级电磁定位传感器也在自主开发中，相关产品的业务规模较小。 4、公司的主营业务是医疗器械精密组件及产品的设计开发、制造和销售。公司主要产品为家用呼吸机 组件、人工植入耳蜗组件和 ...

Group 1 - The medical sector showed strong performance with the largest medical ETF (512170) initially rising over 1% and maintaining positive momentum, outperforming the broader market [1] - Over 1.15 billion CNY of net subscriptions were recorded for the medical ETF, indicating strong investor interest [1] - The ETF has a total scale of 27.7 billion CNY, making it the largest in the medical and healthcare category [3] Group 2 - Huatai Medical reported an expected revenue of 2.584 billion CNY for 2025, representing a year-on-year increase of 25%, with net profit projected at 821 million CNY, up 22% [3] - Other companies within the medical ETF, such as United Imaging and Yirui Technology, are also expected to see net profit growth exceeding 40% [3] - The medical ETF consists of over 50% medical device weight and more than 25% CXO content, covering 12 AI medical and brain-machine interface concept stocks [3] Group 3 - The performance of constituent stocks within the ETF varied, with Huatai Medical leading the gains, rising nearly 7%, while major stocks like Mindray and United Imaging saw declines of nearly 1% [2][3]

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of over 1.15 billion yuan in recent trading sessions [1][5]. Group 1: ETF Performance - The healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1]. - As of February 24, 2026, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year growth of 25%, with a net profit of 821 million yuan, up 22% [3][4]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3]. Group 3: Market Trends - The healthcare sector is characterized by a mix of rising and falling stocks, with Huatai Medical leading gains by rising nearly 7% after a strong earnings report, while major stocks like Mindray and United Imaging saw declines of nearly 1% [1][3].

Core Viewpoint - The healthcare sector is experiencing positive momentum, with the largest healthcare ETF (512170) showing strong performance and attracting significant net inflows of capital [1][8]. Group 1: ETF Performance - On February 27, the healthcare ETF (512170) initially rose over 1% and maintained a positive trend, outperforming the broader market [1][8]. - The ETF saw a net subscription of over 115 million yuan in the previous day, indicating strong investor interest [1][8]. - As of February 24, the healthcare ETF has a total fund size of 27.7 billion yuan, making it the largest in the healthcare sector [5][12]. Group 2: Company Earnings Reports - Huatai Medical reported an expected revenue of 2.584 billion yuan for 2025, representing a year-on-year increase of 25%, with a net profit of 821 million yuan, up 22% [3][10]. - Other companies within the ETF, such as United Imaging and Yirui Technology, also reported significant net profit growth rates exceeding 40% [3][10]. - In contrast, Hotgen Biotech is projected to incur a loss of over 200 million yuan [3][10]. Group 3: Stock Movements - Huatai Medical's stock surged over 11% in early trading, currently leading the sector with a nearly 7% increase [4][10]. - Other stocks like Yingke Medical and Meihua Medical also saw gains, while Jinsong Biological experienced a decline of over 2% [4][10].